← Back to Screener
Novo-Nordisk A/S (NVO)
Price$40.93
Favorite Metrics
Price vs S&P 500 (26W)-35.53%
Price vs S&P 500 (4W)-2.59%
Market Capitalization$176.65B
P/E Ratio (Annual)10.93x
Indicated Dividend Yield (Annual)4.55%
All Metrics
P/CF (Annual)9.40x
Book Value / Share (Quarterly)$6.90
P/TBV (Annual)17.22x
Indicated Dividend (Annual)$1.84
Revenue Growth (3Y)20.43%
Cash Flow / Share (Quarterly)$1.03
Payout Ratio (TTM)68.98%
Price vs S&P 500 (YTD)-22.80%
Gross Margin (TTM)80.98%
Net Profit Margin (TTM)33.14%
EPS (TTM)$3.63
10-Day Avg Trading Volume6.03M
EPS Excl Extra (TTM)$3.63
Revenue Growth (5Y)19.48%
EPS (Annual)$3.63
Dividend / Share (Annual)$1.84
ROI (Annual)31.52%
Gross Margin (Annual)80.98%
Net Profit Margin (5Y Avg)33.85%
Cash / Share (Quarterly)$0.96
P/E Basic Excl Extra (TTM)10.93x
Revenue Growth QoQ (YoY)-7.63%
EPS Growth (5Y)20.66%
P/E Normalized (Annual)10.93x
ROA (Last FY)18.87%
Revenue Growth TTM (YoY)6.43%
EBITD / Share (TTM)$5.31
ROE (5Y Avg)67.14%
Operating Margin (TTM)41.30%
Cash Flow / Share (Annual)$1.03
P/B Ratio5.77x
P/B Ratio (Quarterly)7.44x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)3.96x
Net Interest Coverage (TTM)149.07x
ROA (TTM)20.22%
EPS Growth QoQ (YoY)-4.73%
EV / EBITDA (TTM)8.18x
EPS Incl Extra (Annual)$3.63
Current Ratio (Annual)0.80x
Quick Ratio (Quarterly)0.57x
3-Month Avg Trading Volume7.95M
52-Week Price Return67.26%
EV / Free Cash Flow (Annual)42.21x
P/E Incl Extra (TTM)10.93x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$2.98
P/S Ratio (Annual)3.62x
Asset Turnover (Annual)0.57x
52-Week High$533.40
Operating Margin (5Y Avg)42.72%
EPS Excl Extra (Annual)$3.63
CapEx CAGR (5Y)32.48%
Tangible BV CAGR (5Y)14.46%
26-Week Price Return-31.54%
Quick Ratio (Annual)0.57x
13-Week Price Return-32.90%
Total Debt / Equity (Annual)0.67x
Current Ratio (Quarterly)0.80x
Enterprise Value$193,140.409
Revenue / Share Growth (5Y)20.70%
Asset Turnover (TTM)0.61x
Book Value / Share Growth (5Y)23.06%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.30x
Pretax Margin (Annual)42.24%
Cash / Share (Annual)$0.96
3-Month Return Std Dev62.28%
Gross Margin (5Y Avg)83.54%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)21.66%
EBITDA Interim CAGR (5Y)24.33%
ROE (Last FY)52.79%
Net Interest Coverage (Annual)28.66x
EPS Basic Excl Extra (Annual)$3.63
P/FCF (TTM)17.16x
Receivables Turnover (TTM)4.33x
EV / Free Cash Flow (TTM)42.21x
Total Debt / Equity (Quarterly)0.67x
EPS Incl Extra (TTM)$3.63
Receivables Turnover (Annual)4.33x
ROI (TTM)36.56%
Dividend Growth Rate (5Y)19.05%
P/S Ratio (TTM)3.62x
Pretax Margin (5Y Avg)42.42%
Revenue / Share (Annual)$10.97
Tangible BV / Share (Annual)$2.98
Forward P/E12.46x
Free OCF CAGR (5Y)-0.60%
Price vs S&P 500 (52W)41.90%
P/E Ratio (TTM)10.93x
EPS Growth TTM (YoY)1.76%
Year-to-Date Return-20.92%
5-Day Price Return6.88%
EPS Normalized (Annual)$3.63
ROA (5Y Avg)22.94%
Net Profit Margin (Annual)33.14%
Month-to-Date Return11.39%
Cash Flow / Share (TTM)$2.89
EBITD / Share (Annual)$5.31
EPS Growth (3Y)23.53%
Operating Margin (Annual)41.30%
LT Debt / Equity (Annual)0.61x
P/CF (TTM)9.40x
ROI (5Y Avg)47.01%
P/E Excl Extra (TTM)10.93x
LT Debt / Equity (Quarterly)0.61x
EPS Basic Excl Extra (TTM)$3.63
P/TBV (Quarterly)17.22x
Payout Ratio (Annual)50.53%
P/B Ratio (Annual)7.44x
Dividend / Share (TTM)$1.85
Inventory Turnover (TTM)1.30x
Pretax Margin (TTM)42.24%
Book Value / Share (Annual)$6.90
Price vs S&P 500 (13W)-33.59%
Net Margin Growth (5Y)-0.03%
Dividend Yield (TTM)4.66%
Beta1.72x
P/FCF (Annual)38.61x
Revenue / Share (TTM)$10.96
ROE (TTM)61.10%
52-Week Low$224.25
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
NVONovo-Nordisk A/S | 3.62x | 6.43% | 80.98% | 20.66% | $40.93 |
LLYEli Lilly & Co. | 13.08x | 44.70% | 83.04% | 27.59% | $903.99 |
JNJJohnson & Johnson | 5.94x | 7.87% | 67.95% | 14.90% | $234.54 |
ABBVABBVIE INC. | 6.04x | 8.57% | 71.62% | -2.88% | $208.99 |
MRKMerck & Co., Inc. | 4.41x | 1.31% | 78.55% | 21.23% | $115.46 |
AZNAstraZeneca PLC | 5.28x | 8.63% | 81.31% | 21.88% | $200.47 |
NVSNovartis AG | 4.98x | 8.91% | 75.82% | 15.26% | $149.73 |
ABTAbbott Laboratories | 3.66x | 6.59% | 56.50% | 8.20% | $95.47 |
PFEPfizer Inc. | 2.47x | -1.64% | 75.81% | -3.51% | $27.22 |
BMYBristol-Myers Squibb Co. | 2.47x | -0.22% | 72.63% | — | $58.96 |
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares) | 2.61x | 4.11% | 72.67% | -0.54% | $57.13 |
About
Novo Nordisk is the global leader in diabetes care, commanding approximately one-third of the branded diabetes treatment market. The Danish company manufactures insulins, GLP-1 therapies, oral antidiabetics, and obesity treatments. Its smaller biopharmaceutical segment, representing less than 10% of revenue, develops protein therapies for hemophilia and related disorders.